Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Irritability in Autism Spectrum Disorder
NCT05523895Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of pimavanserin in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Acadia Pharmaceuticals. Primary endpoint: Aberrant Behavior Checklist Irritability Subscale at 6 weeks. Started Aug 2022; status: completed.
02
Drugs
pimavanserin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05523895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523895.